The Enterprise Value as of November 2024 (TTM) for Arcus Biosciences, Inc. (RCUS) is 1.20B

According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.20B. This represents a change of -8.21% compared to the average of 1.31B of the last 4 quarters.

Arcus Biosciences, Inc. (RCUS) Historical Enterprise Value (quarterly & annually)

How has RCUS Enterprise Value performed in the past?

The mean historical Enterprise Value of Arcus Biosciences, Inc. over the last ten years is 1.05B. The current 1.20B Enterprise Value has changed 11.34% with respect to the historical average. Over the past ten years (40 quarters), RCUS's Enterprise Value was at its highest in in the December 2021 quarter at 2.82B. The Enterprise Value was at its lowest in in the March 2018 quarter at -51615845.12.

Arcus Biosciences, Inc. (RCUS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Arcus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arcus Biosciences, Inc. (RCUS) Average Enterprise Value

How has RCUS Enterprise Value performed in the past?

The current Enterprise Value of Arcus Biosciences, Inc. (RCUS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Arcus Biosciences, Inc. (RCUS) Enterprise Value vs. Peers

How is RCUS’s Enterprise Value compared to its peers?

Arcus Biosciences, Inc.’s Enterprise Value is greater than Cullinan Oncology, Inc. (630.54M), greater than Annexon, Inc. (497.96M), less than Structure Therapeutics Inc. (1.75B), greater than Relay Therapeutics, Inc. (692.53M), greater than Day One Biopharmaceuticals, Inc. (963.46M), greater than Acumen Pharmaceuticals, Inc. (139.19M), greater than X4 Pharmaceuticals, Inc. (38.44M), greater than Inozyme Pharma, Inc. (202.73M), greater than VectivBio Holding AG (848.58M), less than PTC Therapeutics, Inc. (3.21B), less than Blueprint Medicines Corporation (6.36B), less than Krystal Biotech, Inc. (5.10B), greater than Intercept Pharmaceuticals, Inc. (915.81M), less than Madrigal Pharmaceuticals, Inc. (7.46B), greater than Immix Biopharma, Inc. (30.53M), greater than CNS Pharmaceuticals, Inc. (209.41K), greater than Hepion Pharmaceuticals, Inc. (5.35M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), greater than Icosavax, Inc. (713.87M), less than Apellis Pharmaceuticals, Inc. (3.90B), greater than iTeos Therapeutics, Inc. (185.75M), greater than TScan Therapeutics, Inc. (184.60M),

Build a custom stock screener for Arcus Biosciences, Inc. (RCUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcus Biosciences, Inc. (RCUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.